NCT05329259View on ClinicalTrials.gov

A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Pneumococcal Disease
Interventions
BIOLOGICAL

13-valent pneumococcal conjugate vaccine

One dose of 13vPnC (0.5mL) will be administered intramuscularly.

Trial Locations (5)

110075

Aakash Healthcare Private Limited, Delhi

305001

Jawahar Lal Nehru Medical College, Ajmer

395002

Nirmal Hospital Pvt Ltd., Surat

560060

BGS Global Institute of Medical Sciences (BGSGIMS), Bangalore

700073

Calcutta School of Tropical Medicine, Kolkata

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05329259 - A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India | Biotech Hunter | Biotech Hunter